{"transactions":[{"id":741330,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39185,"kind":"person","name":"HALL WALLACE L JR","position":1,"cik":"0001762801","reported_name":"HALL WALLACE L JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-11T20:30:19.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":6000,"derivative":{"exercise_price":2.78,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001762801-26-000002","document":"form4-06112026_040615.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000176280126000002/form4-06112026_040615.xml","form_type":"4"}},{"id":1160839,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39185,"kind":"person","name":"HALL WALLACE L JR","position":1,"cik":"0001762801","reported_name":"HALL WALLACE L JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-02T22:19:16.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":202044,"ownership":{"direct":false,"nature":"BioMatrix Partners Ltd."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The initial Form 4 inadvertently listed an incorrect transaction code."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for 250,000 shares of Series A Preferred Stock of Tvardi Therapeutics, Inc. (\"Legacy Tvardi\") pursuant to Agreement and Plan of Merger and Reorganization by and among, the Issuer, CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\") and Legacy Tvardi, as amended (the \"Merger Agreement\") and 11,183 shares of common stock of Issuer issuable upon exchange of convertible notes of Tvardi in the principal amount of $250,000 plus accrued and unpaid interest, pursuant to the Merger Agreement and the terms of the convertible notes."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Received in exchange for 1,000,000 shares of Series A Preferred Stock and 173,448 Series B Preferred Stock of Legacy Tvardi pursuant to the Merger Agreement and 44,665 shares of common stock of Issuer issuable upon exchange of convertible notes of Tvardi in the principal amount of $1,000,000 plus accrued and unpaid interest, pursuant to the Merger Agreement and the terms of the convertible notes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The Reporting Person is a general partner of BioMatrix Partners Ltd. (\"BioMartix\") and may be deemed to share voting and dispositive power of the shares held by Biomatrix but disclaims beneficial ownership of the shares held by such entity except to any pecuniary interest therein."}],"balance_after":202044,"source":{"system":"sec-edgar","filing":"0001415889-25-011859","document":"form4a-05022025_100513.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925011859/form4a-05022025_100513.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1160838,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39185,"kind":"person","name":"HALL WALLACE L JR","position":1,"cik":"0001762801","reported_name":"HALL WALLACE L JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-02T22:19:16.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":44712,"ownership":{"direct":false,"nature":"Firepit Partners, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The initial Form 4 inadvertently listed an incorrect transaction code."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for 250,000 shares of Series A Preferred Stock of Tvardi Therapeutics, Inc. (\"Legacy Tvardi\") pursuant to Agreement and Plan of Merger and Reorganization by and among, the Issuer, CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\") and Legacy Tvardi, as amended (the \"Merger Agreement\") and 11,183 shares of common stock of Issuer issuable upon exchange of convertible notes of Tvardi in the principal amount of $250,000 plus accrued and unpaid interest, pursuant to the Merger Agreement and the terms of the convertible notes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a general partner of Firepit Partners, LP (\"Firepit\") and may be deemed to share voting and dispositive power of the shares held by Firepit but disclaims beneficial ownership of the shares held by such entity except to any pecuniary interest therein."}],"balance_after":44712,"source":{"system":"sec-edgar","filing":"0001415889-25-011859","document":"form4a-05022025_100513.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925011859/form4a-05022025_100513.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1168247,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39185,"kind":"person","name":"HALL WALLACE L JR","position":1,"cik":"0001762801","reported_name":"HALL WALLACE L JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-21T21:15:05.000Z","date":"2025-04-17","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest and become exercisable over three years in 12 equal quarterly installments commencing on July 17, 2025, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":12000,"derivative":{"exercise_price":17.04,"expiration_date":"2035-04-16","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001415889-25-011107","document":"form4-04212025_050401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925011107/form4-04212025_050401.xml","form_type":"4"}},{"id":1169522,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39185,"kind":"person","name":"HALL WALLACE L JR","position":1,"cik":"0001762801","reported_name":"HALL WALLACE L JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-17T22:50:20.000Z","date":"2025-04-15","kind":"other","planned":false,"acquired":true,"shares":202044,"ownership":{"direct":false,"nature":"BioMatrix Partners Ltd."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Received in exchange for 1,000,000 shares of Series A Preferred Stock and 173,448 Series B Preferred Stock of Legacy Tvardi pursuant to the Merger Agreement and 44,665 shares of common stock of Issuer issuable upon exchange of convertible notes of Tvardi in the principal amount of $1,000,000 plus accrued and unpaid interest, pursuant to the Merger Agreement and the terms of the convertible notes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 250,000 shares of Series A Preferred Stock of Tvardi Therapeutics, Inc. (\"Legacy Tvardi\") pursuant to Agreement and Plan of Merger and Reorganization by and among, the Issuer, CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\") and Legacy Tvardi, as amended (the \"Merger Agreement\") and 11,183 shares of common stock of Issuer issuable upon exchange of convertible notes of Tvardi in the principal amount of $250,000 plus accrued and unpaid interest, pursuant to the Merger Agreement and the terms of the convertible notes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a general partner of BioMatrix Partners Ltd. (\"BioMartix\") and may be deemed to share voting and dispositive power of the shares held by Biomatrix but disclaims beneficial ownership of the shares held by such entity except to any pecuniary interest therein."}],"balance_after":202044,"source":{"system":"sec-edgar","filing":"0001415889-25-010984","document":"form4-04172025_060417.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925010984/form4-04172025_060417.xml","form_type":"4"}},{"id":1169521,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39185,"kind":"person","name":"HALL WALLACE L JR","position":1,"cik":"0001762801","reported_name":"HALL WALLACE L JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-17T22:50:20.000Z","date":"2025-04-15","kind":"other","planned":false,"acquired":true,"shares":44712,"ownership":{"direct":false,"nature":"Firepit Partners, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Received in exchange for 250,000 shares of Series A Preferred Stock of Tvardi Therapeutics, Inc. (\"Legacy Tvardi\") pursuant to Agreement and Plan of Merger and Reorganization by and among, the Issuer, CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\") and Legacy Tvardi, as amended (the \"Merger Agreement\") and 11,183 shares of common stock of Issuer issuable upon exchange of convertible notes of Tvardi in the principal amount of $250,000 plus accrued and unpaid interest, pursuant to the Merger Agreement and the terms of the convertible notes."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 250,000 shares of Series A Preferred Stock of Tvardi Therapeutics, Inc. (\"Legacy Tvardi\") pursuant to Agreement and Plan of Merger and Reorganization by and among, the Issuer, CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\") and Legacy Tvardi, as amended (the \"Merger Agreement\") and 11,183 shares of common stock of Issuer issuable upon exchange of convertible notes of Tvardi in the principal amount of $250,000 plus accrued and unpaid interest, pursuant to the Merger Agreement and the terms of the convertible notes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a general partner of Firepit Partners, LP (\"Firepit\") and may be deemed to share voting and dispositive power of the shares held by Firepit but disclaims beneficial ownership of the shares held by such entity except to any pecuniary interest therein."}],"balance_after":44712,"source":{"system":"sec-edgar","filing":"0001415889-25-010984","document":"form4-04172025_060417.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000141588925010984/form4-04172025_060417.xml","form_type":"4"}}]}